Atezolizumab

Generic Name: Atezolizumab

Brand Names: Tecentriq

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1380723-44-3

Unique Ingredient Identifier: 52CMI0WC3Y

Background: Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.

Indication: Atezolizumab has approved indications for the following conditions:

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Hepatocellular Carcinoma (HCC)

Melanoma

Alveolar Soft Part Sarcoma (ASPS)

Associated Conditions: Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma

Associated Therapies: -

Clinical Trials

A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Atezolizumab
Drug: rHuPH20

First Posted Date: 2018-11-08

Last Posted Date: 2024-10-16

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 438

Registration Number: NCT03735121

Locations: 🇨🇱
James Lind Centro de Investigación Del Cáncer, Temuco, Chile
🇨🇱
ONCOCENTRO APYS; Oncología, Vina Del Mar, Chile
🇬🇹
INTEGRA Cancer Institute, Ciudad de Guatemala, Guatemala

and more 84 locations

A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)

Phase 1

Completed

Conditions: Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

Interventions: Drug: gilteritinib
Drug: atezolizumab

First Posted Date: 2018-11-05

Last Posted Date: 2024-11-28

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 11

Registration Number: NCT03730012

Locations: 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸
Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
University of Kentucky, Lexington, Kentucky, United States

and more 9 locations

A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Placebo
Drug: Atezolizumab
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Paclitaxel
Drug: Trastuzumab
Drug: Pertuzumab
Drug: Trastuzumab Emtansine

First Posted Date: 2018-11-01

Last Posted Date: 2024-11-05

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 454

Registration Number: NCT03726879

Locations: 🇺🇸
Tennessee Oncology - Nashville, Nashville, Tennessee, United States
🇺🇸
HCA Midwest Division, Kansas City, Missouri, United States
🇺🇸
New York University Medical Center PRIME; NYU Langone Medical Center, New York, New York, United States

and more 73 locations

FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Bevacizumab
Drug: Irinotecan
Drug: Oxaliplatin
Drug: L-Leucovorin
Drug: 5-fluorouracil
Drug: Atezolizumab

First Posted Date: 2018-10-26

Last Posted Date: 2023-10-12

Lead Sponsor: Gruppo Oncologico del Nord-Ovest

Target Recruit Count: 218

Registration Number: NCT03721653

Locations: 🇮🇹
Francesca Vannini, Pisa, Italia, Italy

Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

Phase 2

Terminated

Conditions: NSCLC Stage IV
NSCLC, Recurrent

Interventions: Drug: Carboplatin
Drug: Pemetrexed
Drug: Atezolizumab
Drug: Bevacizumab

First Posted Date: 2018-10-22

Last Posted Date: 2023-03-01

Lead Sponsor: Nasser Hanna

Target Recruit Count: 30

Registration Number: NCT03713944

Locations: 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States
🇺🇸
Indiana Univeristy Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

and more 4 locations

Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab

Phase 2

Completed

Conditions: Colorectal Neoplasms
Neoplasm Metastasis
Colonic Neoplasms
Rectal Neoplasms

Interventions: Drug: Atezolizumab
Drug: Bevacizumab
Drug: Oxaliplatin
Drug: Levoleucovorin
Drug: 5-FU

First Posted Date: 2018-10-09

Last Posted Date: 2024-01-31

Lead Sponsor: Asan Medical Center

Target Recruit Count: 20

Registration Number: NCT03698461

Locations: 🇰🇷
Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of

Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy

Phase 2

Active, not recruiting

Conditions: Bladder Cancer

Interventions: Drug: Atezolizumab

First Posted Date: 2018-10-05

Last Posted Date: 2024-12-04

Lead Sponsor: UNICANCER

Target Recruit Count: 79

Registration Number: NCT03697850

Locations: 🇫🇷
Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷
Centre Georges Francois Leclerc, Dijon, France
🇫🇷
Institut Bergonie, Bordeaux, France

and more 9 locations

A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer

Phase 1

Completed

Conditions: OVARIAN CANCER

Interventions: Drug: Cobimetinib
Drug: Niraparib
Drug: Atezolizumab

First Posted Date: 2018-10-04

Last Posted Date: 2023-08-14

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 77

Registration Number: NCT03695380

Locations: 🇺🇸
Medical College of Georgia; Obstetrics & Gynecolog, Augusta, Georgia, United States
🇺🇸
Stephenson Cancer Center Investigational Pharmacy, Oklahoma City, Oklahoma, United States
🇺🇸
Florida Hospital Cancer Institute; Clinical Research Department, Orlando, Florida, United States

and more 17 locations

A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma

Phase 3

Withdrawn

Conditions: Renal Cell Carcinoma

Interventions: Drug: Atezolizumab
Drug: Bevacizumab

First Posted Date: 2018-10-03

Last Posted Date: 2018-11-15

Lead Sponsor: Hoffmann-La Roche

Registration Number: NCT03693573

The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)

Phase 2

Completed

Conditions: Endometrial Cancer
Uterine Carcinosarcoma

Interventions: Drug: Rucaparib
Drug: Bevacizumab
Drug: Atezolizumab

First Posted Date: 2018-10-03

Last Posted Date: 2023-08-31

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 30

Registration Number: NCT03694262

Locations: 🇺🇸
Froedtert Lutheran Memorial Hospital, Milwaukee, Wisconsin, United States
🇺🇸
St. Luke's Hospital and Health Network, Bethlehem, Pennsylvania, United States
🇺🇸
Mount Sinai, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy